OrisDX has announced the availability of Oro Lesion, a noninvasive, saliva-based DNA test designed to detect biomarkers associated with oral cavity squamous cell carcinoma (OCSCC). The test is offered as a laboratory-developed test (LDT) through a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP).
According to the company, Oro Lesion is the first noninvasive, saliva-based DNA test for OCSCC, demonstrating 94% sensitivity, 98% specificity, a positive predictive value of 96%, and a negative predictive value of 97% in validation testing. The test is intended for adults aged 18 years and older who present with an indeterminate oral lesion and is available through dental and medical professionals.
Head and neck cancer is the sixth most common cancer worldwide, and delayed diagnosis remains a significant concern. Five-year survival rates for patients diagnosed at advanced stages can be as low as 25%, compared with survival rates approaching 90% when disease is detected early. An estimated 1.6 million to 4.9 million adults annually present to dental professionals with oral lesions that may warrant further evaluation.
“As a head and neck cancer survivor, I know how hard it can be to wait for answers when you notice a change in your mouth. Getting it checked promptly by a dental or medical professional and knowing what comes next can make a real difference for patients and their families," said Cathy Hapenney, head and neck cancer survivor and advocate.
Oro Lesion identifies biomarkers associated with acquired, or somatic, mutations in cancer-related DNA obtained from whole cells collected through a salivary rinse. Following a conventional oral examination, clinicians may provide patients with a collection kit for use in the dental or medical office. Alternatively, the kit can be mailed directly to the patient's home for self-collection.
Samples are returned to the OrisDX laboratory using a prepaid mailer and analyzed through an automated testing system. Results are reported as either "detected" or "not detected" for biomarkers associated with OCSCC. According to the company, results may be available in as little as two weeks and are communicated to the prescribing clinician and patient through its Oris Bridge platform. Patients with positive results may receive additional navigation support to facilitate referral to a surgeon for further evaluation.
“Oral cancer is most treatable when it’s caught early, and too many cases aren’t. OrisDX gives clinicians a simple, noninvasive way to find it sooner, with accuracy we have validated in a CLIA-certified, CAP-accredited lab. We designed the test to be accurate, easy for patients to use, and widely accessible,” said Nishant Agrawal, MD, a UChicago Medicine surgeon and co-inventor of the test.
“Our hope is that earlier detection will save lives,” added Nishant Agrawal, MD.
"For far too long, patients facing a suspicious oral lesion have found themselves caught in a fragmented gray zone between routine dental care and complex medical oncology—facing anxiety, delays, and invasive unknowns,” said Harald Steltzer, CEO of OrisDX. “With the launch of Oro Lesion, we are directly closing that divide. By arming clinicians with definitive, non-invasive molecular clarity at the earliest point of concern, we aren’t just advancing diagnostics; we are fundamentally reshaping the patient journey. Our mission is to put the individual first, replacing prolonged uncertainty with swift, actionable answers, and ensuring that every patient seamlessly navigates from the dental chair to the right specialized care without falling through the cracks."
Oro Lesion is currently available in the United States through healthcare providers. OrisDX also plans to expand the test to include human papillomavirus (HPV) biomarkers associated with cancers that commonly arise in the oropharynx.
For additional information, visit www.orisdx.com/orolesion.